The inhibitory effects of transforming growth factor-beta-1 (TGF-β1) in autoimmune diseases

Journal of Autoimmunity

Volumn 14, Issue 1, 2000, Pages 23-42

  Prud'homme, Gérald J ^a   Piccirillo, Ciriaco A ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

CTLA 4; Regulatory T cell; Th3; Tolerance; Transforming growth factor beta

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; TRANSFORMING GROWTH FACTOR BETA1;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; CYTOKINE RELEASE; DIABETES MELLITUS; EFFECTOR CELL; ENDOTHELIUM CELL; GENE THERAPY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; KNOCKOUT MOUSE; LEUKOCYTE ADHERENCE; LYMPHOCYTE CLONE; MACROPHAGE; MEMORY CELL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 0033953109     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.1999.0339     Document Type: Review

References (235)

1. Derynck R., Choy L. Transforming growth factor-β and its receptors. Thompson A. The cytokine handbook. 1998;593-638 Academic Press, New York.
2. Ruscetti F.W., Birchenall-Roberts M.C., McPherson J.M., Wiltrout R.H. Transforming growth factor β1. Mire-Luis A., Thorpe R. Cytokines. 1998;415-432 Academic Press, San Diego.
3. Letterio J.J., Roberts A.B. Regulation of immune responses by TGF-β Ann. Rev. Immunol. 16:1998;137-161.
4. McCartney-Francis N.L., Frazier-Jessen M., Wahl S.M. TGF-beta: a balancing act. Int. Rev. Immunol. 16:1998;553-580.
5. Engel M.E., Datta P.K., Moses H.L. Signal transduction by transforming growth factor-beta: a cooperative paradigm with extensive negative regulation. J. Cell. Biochem. 30-31:1998;111-122.
6. Roberts A.B., Sporn M.B. The transforming growth factor-betas. Sporn M., Roberts A. Peptide growth factors and their receptors. 1990;419-472 Springer Verlag, New York.
7. Schmid P., Cox D., Bilbe G., Rainer M., McMaster G.K. Differential expression of TGF-β1, β2 and β3 genes during mouse embryogenesis. Development. 11:1991;117-130.
8. Roberts A.B., Sporn M.B. Differential expression of the TGF-β isoforms in embryogenesis suggests specific roles in developing and adult tissues. Mol. Report. Dev. 32:1992;91-98.
9. Fontana A., Constam D.B., Frei K., Malipiero V., Pfister H.W. Modulation of the immune response by TGF-β Int. Arch. Allergy. Immunol. 99:1992;1-7.
10. Kehrl J.H., Wakefield L.M., Roberts A.B., Jackowlew S., Alvarez M., Derynck R., Sporn M.B., Fauci A.S. The production of TGF-β1 by human T lymphocytes and its potential role in the regulation of T cell growth. J. Exp. Med. 165:1986;1037-1050.
11. Bascom C., Wolfshohl J., Coffey R. Complex regulation of transforming growth factor β1, β2 and β3 mRNA expression in mouse fibroblasts and keratinocytes by transforming growth factors β1 and β2. Mol. Cell. Biol. 9:1989;5508-5515.
12. Derynck R., Jarrett J.A., Chen E.Y., Eaton D.H., Bell J.R., Assoian R.K., Roberts A.B., Sporn M.B., Goeddel D.V. Human transforming growth factor-β from human platelets. A high molecular weight complex containing precursor sequences. J. Biol. Chem. 163:1985;7646-7654.
13. Wakefield L.M., Smith D.M., Flanders K.C., Sporn M.B. Latent transforming growth factor-β from human platelets. A high molecular weight complex containing precursor sequences. J. Biol. Chem. 263:1988;7646-7654.
14. Kingsley D.M. The TGF-β superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev. 8:1994;133-146.
15. Cheifetz S., Massagué J. Transforming growth factor-β (TGF-β) receptor proteoglycan. Cell surface expression and ligand binding in the absence of glycosaminoglycan chains. J. Biol. Chem. 264:1989;12025-12028.
16. Geiser A.G., Burmester J.K., Webbink R., Roberts A.B., Sporn M.B. Inhibition of growth by transforming growth factor-β following fusion of two nonresponsive human carcinoma cell lines. J. Biol. Chem. 267:1992;2588-2593.
17. Chen R.H., Ebner R., Derynck R. Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-β activities. Science. 260:1993;1335-1338.
18. Ebner R., Chen R.H., Shum L., Lawler S., Zionchek T.F., Lee A., Lopez A.R., Derynck R. Cloning of a type I TGF-β receptor and its effect on TGF-β binding to the type II receptor. Science. 260:1993;1344-1348.
19. Wrana J.L., Attisano L., Wieser R., Ventura F., Massagué J. Mechanism of activation of the TGF-β receptor. Nature. 370:1994;341-347.
20. Derynck R., Feng X.H. TGF-receptor signaling. BBA Rev. Cancer. 1333:1997;F105-F150.
21. Border W.A., Ruoslahti E. Transforming growth factor-beta in disease: The dark side of tissue repair. J. Clin. Invest. 90:1992;1-7.
22. Yamaguchi Y., Mann D.M., Ruoslahti E. Negative regulation of transforming growth factor-β by the proteoglycan decorin. Nature. 346:1990;281-284.
23. Yamashita H., Ichijo H., Grimsby S., Moren A., Ten Dijke P., Miyazono K. Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factor-β J. Biol. Chem. 269:1994;13231-13237.
24. O'Connor-McCourt M.D., Wakefield L.M. Latent transforming growth factor-β in serum. A specific complex with α-macroglobulin. J. Biol. Chem. 262:1987;14090-14099.
25. Murphy-Ullrich J.E., Schultz-Sherry S., Hook M. Transforming growth factor-β complexes with thrombospondin. Mol. Biol. Cell. 3:1992;181-188.
26. 2-macroglobulin receptor-dependent mechanism for the plasma clearance of transforming growth factor-β1 in mice. J. Clin. Invest. 87:1991;39-44.
27. Fava R., McClure D.B. Fibronectin-associated transforming growth factor. J. Cell. Physiol. 131:1987;184-189.
28. Paralkar V.M., Vukicevic S., Reddi A.H. Transforming growth factor β type 1 binds to collagen IV of basement membrane matrix: implications for development. Dev. Biol. 143:1991;303-308.
29. Lowrance J.H., O'Sullivan F.X., Caver T.E., Waegell W., Gresham H.D. Spontaneous elaboration of transforming growth factor beta suppresses host defense against bacterial infection in autoimmune MRL/lpr mice. J. Exp. Med. 180:1994;1693-1703.
30. Rowley D.A., Becken E.T., Stach R.M. Autoantibodies produced spontaneously by young lpr mice carry transforming growth factor beta and suppress cytotoxic T lymphocyte responses. J. Exp. Med. 181:1995;1875-1880.
31. Caver T.E., O'Sullivan F.X., Gold L.I., Gresham H.D. Intracellular demonstration of active TGF-β1 in B cells and plasma cells of autoimmune mice. IgG-bound TGF-β1 suppresses neutrophil function and host defense against Staphylococcus aureus infection. J. Clin. Invest. 98:1996;2496-2506.
32. Stach R.M., Rowley D.A. A first or dominant immunization. II. Induced immunoglobulin carries transforming growth factor beta and suppresses cytolytic T cell responses to unrelated alloantigens. J. Exp. Med. 178:1993;841-852.
33. Gresham H.D., Ray C.J., O'Sullivan F.X. Defective neutrophil function in the autoimmune mouse strain MRL/lpr. Potential role of transforming growth factor-beta. J. Immunol. 146:1991;3911-3921.
34. Bouchard C., Galinha A., Tartour E., Fridman W.H., Sautes C. A transforming growth factor beta- like immunosuppressive factor in immunoglobulin G-binding factor. J. Exp. Med. 182:1995;1717-1726.
35. Lopez A.R., Cook J., Deiningen P.L., Derynck R. Dominant negative mutants of transforming growth factor-β1 inhibit the secretion of different transforming growth factor-β isoforms. Mol. Cell. Biol. 12:1992;1674-1679.
36. Miyazono K., Yuki K., Takaku F., Wernstedt C., Kanzaki T., Olofsson A., Hellman U., Heldin C.H. Latent forms of TGF-β: structure and biology. Ann. NY Acad. Sci. 593:1990;51-58.
37. Sato Y., Rifkin D.B. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-β1-like molecule by plasmin during co-culture. J. Cell. Biol. 109:1989;309-315.
38. Dennis P.A., Rifkin D.B. Cellular activation of latent transforming growth factor-β requires binding to the cation-independent mannose 6-phosphate/ insulin-like growth factor type II receptor. Proc. Natl. Acad. Sci. 88:1991;580-584.
39. Wallick S.C., Figari I.S., Morris R.E., Levison A.D., Palladino M.A. Immunoregulatory role of transforming growth factor (TGF-) in development of killer cells: comparison of active and latent TGF-1. J. Exp. Med. 172:1990;1777-1784.
40. Alexandrow M.G., Moses H.L. Transforming factor growth and cell cycle regulation. Cancer Res. 55:1995;1452-1457.
41. Moses H.L., Yang E.Y., Pietentol J.A. TGF-β stimulation and inhibition of cell proliferation: new mechanistic insights. Cell. 63:1990;245-247.
42. Ruscetti F., Varesio L., Ochoa A., Ortaldo J. Pleiotropic effects of transforming growth factor-beta on cells of the immune system. Ann. NY Acad. Sci. 685:1993;488-500.
43. Ruscetti F.W., Palladino M.A. Transforming growth factor beta and the immune system. Prog. Growth factor Res. 3:1991;159-175.
44. Kehrl J.H., Roberts A.B., Wakefield L.M., Jakowlew S., Sporn M.B., Fauci A.S. Transforming growth factor-β is an important immunomodulating protein for human B lymphocytes. J. Immunol. 137:1986;3855-3860.
45. Sher A., Gazzinelli R.T., Oswald I.P., Clerici M., Kullberg M., Pearce E.J., Berzofsky J.A., Mosmann T.R., James S.L., Morse H.C. Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infections. Immunol. Rev. 127:1992;183-204.
46. Kehrl J.H., Thevenin C., Rieckmann P., Fauci A.S. Transforming growth factor-β suppresses human B lymphocyte Ig production by inhibiting synthesis and the switch from the membrane form to the secreted form of Ig mRNA. J. Immunol. 146:1991;4016-4022.
47. Rook A.H., Kehrl J.H., Wakefield L.M., Roberts A.B., Sporn M.B., Burlington D.B., Lane H.C., Fauci A.S. Effects of transforming growth factor β on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J. Immunol. 136:1986;3916-3920.
48. Kuppner M.C., Hamou M.F., Bodmer S., Fontana A., De Tribolet N. The glioblastoma-derived T-cell suppressor factor/transforming growth factor β2 inhibits the generation of lymphokine-activated killer (LAK) cells. Int. J. Cancer. 42:1988;562-567.
49. Wahl S.M., Hunt D.A., Wong H.L., Dougherty S., McCartney-Francis N., Ellingsworth L., Schmidt J.A., Hall G., Roberts A.B. Transforming growth factor-β is a potent immunosuppressive agent that inhibits IL-1 dependent lymphocyte proliferation. J. Immunol. 140:1988;3026-3032.
50. Wahl S.M., Hunt D.A., Bansal G., McCartney-Francis N., Ellingsworth L., Allen J.B. Bacterial cell wall-induced immunosuppression. Role of transforming growth factor β J. Exp. Med. 168:1988;1403-1417.
51. Ortaldo J.R., Mason A.T., O'Shea J.J., Smith M.J., Falk L.A., Kennedy A.C.S., Longo D.L., Ruscetti F.W. Mechanistic studies of transforming growth factor-beta inhibition of IL-2 dependent activation of CD3-large granular lymphocyte functions. Regulation of IL-2Rβ (p75) signal transduction. J. Immunol. 146:1991;3791-3798.
52. Schmitt E., Hoehn P., Huels C., Goedert S., Palm N., Rude E., Germann T. T helper type 1 development of naïve CD4+T cells requires the coordinate action of interleukin 12 and interferon gamma and is inhibited by transforming growth factor beta. Eur. J. Immunol. 24:1994;793-798.
53. Bright J.J., Kerr L.D., Sriram S. TGF-β inhibits IL-2 induced tyrosine phosphorylation and activation of Jak-1 and Stat 5 in T lymphocytes. J. Immunology. 159:1997;175-183.
54. Szabo S.J., Dighe A.S., Gubler U., Murphy K.M. Regulation of the interleukin (IL)-12R beta 2 subunit expression in the developing T helper 1 (Th1) and Th2 cells. J. Exp. Med. 185:1997;817-824.
55. Strober W., Kelsall B., Fuss I., Marth T., Ludviksson B., Ehrhardt R. Reciprocal IFN-gamma and TGF-beta response regulate the occurrence of mucosal inflammation. Immunol. Today. 18:1997;61-64.
56. Vodovotz Y., Bogdan C. Control of nitric oxide synthase expression by transforming growth factor-beta: implications for homeostasis. Prog. Growth Factor Res. 5:1994;341-351.
57. Vodovotz Y., Bogdan C., Paik J., Xie Q.W., Nathan C. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor-β J. Exp. Med. 178:1993;605-613.
58. Tsunawaki S., Sporn M., Ding A., Nathan C. Deactivation of macrophages by transforming growth factor β Nature. 334:1988;260-262.
59. Gorham J.D., Guler M.L., Fenoglio D., Gubler U., Murphy K.M. Low dose TGF-β attenuates IL-12 responsiveness in murine Th cells. J. Immunol. 161:1998;1664-1670.
60. Czarniecki C.W., Chiu H.H., Wong G.H.W., McCabe S.M., Palladino M.A. Transforming growth factor-beta 1 modulates the expression of class II histocompatibility antigens on human cells. J. Immunol. 140:1988;4217-4223.
61. Gamble J.R., Khew-Goodall Y., Vadas M.A. Transforming growth factor β inhibits E-selectin expression on human endothelial cells. J. Immunol. 150:1993;4494-4503.
62. Dickson K., Philip A., Warshawsky H., O'Connor-McCourt M., Bergeron J.J.M. Specific binding of endocrine transforming growth-β1 to vascular endothelium. J. Clin. Invest. 95:1995;2539-2554.
63. Granstein R.D., Straszewski R., Knisely T.L., Zeira E., Nazareno R., Latina M., Albert D.M. Aqueous humor contains transforming growth factor-β and a small (less than 3500 daltons) inhibitor of thymocyte proliferation. J. Immunol. 144:1990;3021.
64. Jiang L.Q., Streilein J.W. Immune privilege extended to allogeneic tumor cells in the vitreous cavity. Invest. Ophthalmol. Vis. 32:1991;224.
65. Clark D.A., Flanders K.C., Banwatt D., Millar-Book W., Manuel J., Stedronska-Clark J., Rowley B. Murine pregnancy decidua produces a unique immunosuppressive molecule related to transforming growth factor beta-2. J. Immunol. 144:1990;3008-3014.
66. Godkin J.D., Dore J.J. Transforming growth factor and the endometrium. Rev. in Reproduction. 3:1998;1-6.
67. Pollanen P., von Euler M., Jahnukainen K., Saari T., Parvinen M., Sainio-Pollanen S., Soder O. Role of transforming growth factor beta in testicular immunosuppression. J. Reprod. Immunol. 24:1993;123.
68. Fabry Z., Topham D.J., Fee D., Herlein J., Carlino A., Hart M.N., Sriram S. TGF-β2 decreases migration of lymphocytes in vitro and homing of cells into central nervous system in vivo. J. Immunol. 155:1995;325.
69. Chambaz E.M., Souchelnitskiy S., Pellerin S., Defaye G., Cochet C., Feige J.J. Transforming growth factors-beta s: a multifunctional cytokine family: implication in the regulation of adrenocortical cell endocrine functions. Horm. Res. 45:1996;222.
70. Schwartz R.H. Immunological tolerance. Paul W.E. Fundamental immunology. 1999;701-739 Lippincott-Raven Publishers, Philadelphia.
71. Ferguson T.A., Griffith T.S. A vision of cell death: insights into immune privilege. Immunol. Rev. 156:1997;167-184.
72. Mor G., Gutierrez L.S., Eliza M., Kahyaoglu F., Arici A. Am. J. Reprod. Immunol. 40:1998;89-94.
73. Taylor A.W., Alard P., Yee D.G., Streilein J.W. Aqueous humor induces transforming growth factor-beta (TGF-beta)-producing regulatory T-cells. Current Eye Research. 16:1997;900-908.
74. Gordon-Thomson C., de Iongh R.U., Hales A.M., Chamberlain C.G., McAvoy S.W. Differential cataractogenic potency of TGF-beta 1, -beta 2, -beta3 and their expression with postnatal eye. Invest. Ophthal. Vis. Sci. 39:1998;1399-1409.
75. Ishida K., Yoshimura N., Yoshida M., Honda Y. Upregulation of transforming growth factor-beta after panretinal photocoagulation. Invest. Ophthal. Vis. Sci. 39:1998;801-807.
76. D'Orazio T.J., Niederkorn J.Y. A novel role for TGF-beta and IL-10 in the induction of immune privilege. J. Immunol. 160:1998;2089-2098.
77. Takeuchi, M. Kosiewicz, M.M. Alard, P. Streilein, J.W. On the mechanisms by which transforming growth factor-beta 2 alters antigen-presenting abilities of macrophages on T cell activation, Eur. J Immunol. 27, 1648, 1656.
78. Kosiewicz M.M., Streilein J.W. Intraocular injection of class II-restricted peptide induces an unexpected population of CD8 regulatory cells. J. Immunol. 157:1996;1905-1912.
79. Streilein J.W., Ksander B.R., Taylor A.W. Immune deviation in relation to ocular immune privilege. J. Immunol. 158:1997;3557-3560.
80. Swain S.L., Huston G., Tonkonogy S., Weinberg A. Transforming growth factor beta and IL-4 cause helper T cell precursors to develop into distinct effector helper cells that differ in lymphocyte secretion pattern and cell surface phenotype. J. Immunol. 147:1991;2991-3000.
81. Letterio J.L., Roberts A.B. TGF-β: a critical modulator of immune cell function. Clin. Immunol. Immunopathol. 84:1997;244-250.
82. Barral-Netto M., Barral A., Brownell C.E., Skeiky Y.A., Ellingsworth L.R., Twardsik D.R., Reed S.G. Transforming growth factor beta in leishmanial infection: a parasite escape mechanism. Science. 257:1992;545-548.
83. Bright J.J., Sriram S. TGF-β inhibits IL-12 induced activation of Jak-STAT pathway in T lymphocytes. J. Immunol. 161:1998;1772-1777.
84. Yotsukura J., Huang H., Singh A.K., Shichi H. Regulatory cells generated by testicular tolerization to retinal S-antigen: possible involvement of IL-4, IL-10, and TGF-beta in the suppression of experimental autoimmune uveoretinitis. Cell. Immunol. 182:1998;89-98.
85. Graham C.H., Lala P.K. Mechanism of control of trophoblast invasion in situ. J. Cell. Physiol. 148:1991;228-234.
86. Lawton L.N., Bonaldo M.F., Jelenc P.C., Qiu L., Baumes S.A., Marcelino R.A., de Jesus G.M., Wellington S., Knowles J.A., Warburton D., Brown S., Soares M.B. Identification of a novel member of the TGF-beta superfamily highly expressed in human placenta. Gene. 203:1997;17-26.
87. Josien R., Douillard P., Guillot C., Muschen M., Anegon I., Chetritt J., Menoret S., Vignes C., Soulillou J.P., Cuturi M.C. A critical role for transforming growth factor-beta in donor transfusion-induced allograft tolerance. J. Clin. Invest. 102:1998;1920-1926.
88. Lee W.C., Zhong C., Qian S., Wan Y., Gauldie J., Mi Z., Robbins P.D., Thomson A.W., Lu L. Phenotype, function, and in vivo migration and survival of allogeneic dendritic cells progenitors genetically engineered to express TGF-beta. Transplantation. 66:1998;1810-1817.
89. Brouard S., Blancho G., Moreau A., Heslan J.M., Cuturi M.C., Soulillou J.P. Long-term survival of hamster-to-rat cardiac xenografts in the absence of a Th2 shift. Transplantation. 65:1998;1555-1563.
90. Merly F., Huard C., Asselin I., Robbins P.D., Tremblay J.P. Anti-inflammatory effect of transforming growth factor-beta 1 in myoblast transplantation. Transplantation. 65:1998;793-799.
91. Qin L., Ding Y., Bromberg J.S. Gene transfer of transforming growth factor-beta 1 prolongs murine cardiac allograft survival by inhibiting cell-mediated immunity. Human Gene Therapy. 7:1996;1981-1988.
92. Mowat A.M., Garside P., Fitton L.A., Higley H.R., Carlino J.A. Regulatory activity of endogenous and exogenous transforming growth factor beta in experimental intestinal immunopathology. Growth Factors. 13:1996;75-85.
93. Li B., Sehajpal P.K., Khanna A., Vlassara H., Cerami A., Stenzel K.H., Suthanthiran M. Differential regulation of transforming growth factor beta and inteleukin 2 genes in human T cells: demonstration by usage of novel competitor DNA constructs in the quantitative polymerase chain reaction. J. Exp. Med. 174:1991;1259-1262.
94. Khanna A.K., Cairns V.R., Becker C.G., Hosenpud J.D. Transforming growth factor (TGF)-beta mimics and anti-TGF-beta antibody abrogates the in vivo effects of cyclosporine-Demonstration of a direct role of TGF-beta in immunosuppression and nephrotoxicity of cyclosporine. Transplantation. 67:1999;882-889.
95. Hojo M., Morimoto T., Maluccio M., Asano T., Morimoto K., Lagman M., Shimbo T., Suthanthiran M. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 397:1999;530-534.
96. Faria A.M., Weiner H.L. Oral tolerance: mechanisms and therapeutic applications. Adv. Immunol. 73:1999;153-264.
97. Chen Y., Kuchroo V.K., Inobe J., Hafler D.A., Weiner H.L. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science. 265:1994;1237-1240.
98. +T cell lines. J. Exp. Med. 185:1997;1769-1775.
99. +T cell population which inhibits antigen-specific T cell responses. Nature. 389:1997;737-742.
100. Mason D., Powrie F. Control of immune pathology by regulatory T cells. Current Opinion in Immunology. 10:1998;649-655.
101. +T cell subset that inhibits this autoimmune potential. J. Exp. Med. 177:1993;627-636.
102. -thymocytes in the prevention of autoimmune diabetes. Biochem. Soc. Trans. 25:1997;620-624.
103. Greiner D.L., Malkani S., Kanaitsuka T., Bortell R., Doukas J., Rigby M., Whalen B., Stevens L.A., Moss J., Mordes J.P., Rossini A.A. The T cell marker RT6 in a rat model of autoimmune diabetes. Adv. Exp. Med. Biol. 419:1997;209-216.
104. Seddon B., Mason D. Regulatory T cells in the control of autoimmunity: the essential role of transforming growth factor beta and interleukin 4 in the prevention of autoimmune thyroiditis in rats by peripheral CD4(+)CD45RC(-) cells and CD4(+)CD8(-) thymocytes. J. Exp. Med. 189:1999;279-288.
105. Kallapur S., Shull M., Doetschman T. Phenotypes of TGFβ knockout mice. Durum S.K., Mueege K. Cytokine knockouts. 1998;315-334 Humana Press, Totowa.
106. Kulkarni A.B., Letterio J.J. The transforming growth factor-β1 knockout mouse: the phenotype and its implications for TGFβ1 function. Durum S.K., Muegge K. Cytokine knockouts. 1998;369-400 Humana Press, Totowa.
107. Hines H.L., Kulkarni A.B., McCarthy J.B., Tian H., Ward J.M., Christ M., McCartney-Francis N.L., Furcht L.T., Karlsson S., Wahl S.M. Synthetic fibronectin peptides interrupt inflammatory cell infiltration in transforming growth factor beta 1 knock-out mice. Proc. Natl. Acad. Sci. 91:1994;5187-5191.
108. Diebold R.J., Eis M.J., Yin M., Ormsby I., Boivin G.P., Darrow B.J., Saffity J.E., Doeschman T. Early onset multifocal inflammation in the transforming growth factor β1-null mouse is lymphocyte dependent. Proc. Natl. Acad. Sci. 92:1995;12215-12219.
109. Shull M.M., Ormsby I., Kier A.B., Pawlowski S., Diebold R.J., Yin M., Allen R., Sidman C., Proetzel G., Calvin D., Annunziata N., Doetschman T. Targeted disruption of the mouse TGF-β1 gene results in multifocal inflammatory disease. Nature. 359:1992;693-699.
110. Sprent J. The thymus and central tolerance. Horm. Met. Res. 28:1996;294-295.
111. Sprent J. Central tolerance of T cells. Int. Rev. Immunol. 13:1995;95-105.
112. Takahama Y., Letterio J.J., Harumi-Suzuki H., Farr A.G., Singer A. Early progression of thymocytes along the CD4/CD8 developmental pathway is regulated by a subset of thymic epithelial cells expressing transforming growth factor β J. Exp. Med. 179:1994;1495-1506.
113. +T cells. J. Exp. Med. 188:1998;1849-1857.
114. +T cells. Immunol. Rev. 165:1998;231-247.
115. Mandelbrot D.A., McAdam A.J., Sharpe A.H. B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). J. Exp. Med. 189:1999;435-440.
116. Bluestone J.A., Khattri R., van Seventer G.A. Accessory molecules. Paul W.E. Fundamental Immunology. 1999;449-478 Lippincott-Raven Publishers, Philadelphia.
117. Issazadeh S., Navikas V., Schaub M., Sayegh M., Khoury S. Kinetics of expression of costimulatory molecules and their ligands in murine relapsing experimental autoimmune encephalomyelitis. J. Immunol. 161:1998;1102-1104.
118. Weinberg A.D., Whitman R., Swain S.L., Morrison W.J., Wyrick G., Hoy C., Vandenbark A.A., Offner H. Target organ-specific up-regulation of the MRC OX-40 marker and selective production of Th1 lymphokine mRNA by encephalitogenic T helper cells isolated from the spinal cord of rats with EAE. J. Immunol. 148:1992;2109-2117.
119. Lee H.M., Rich S. Co-stimulation of T cell proliferation by transforming growth factor-beta 1. J. Immunol. 147:1991;1127-1133.
120. Genestier L., Kasibhatla S., Brunner T., Green D.R. Transforming growth factor beta 1 inhibits Fas ligand expression and subsequent activation-induced cell death in T cells via downregulation of c-Myc. J. Exp. Med. 189:1999;231-239.
121. Cerwenka A., Kovar H., Majdic O., Holter W. Fas- and activation-induced apoptosis are reduced in human T cells preactivated in the presence of TGF-beta 1. J. Immunol. 156:1996;459-464.
122. +T cells from T cell receptor transgenic mice. J. Exp. Med. 176:1992;1091-1098.
123. Inobe J-I, Slavin A.J., Komagata Y., Chen Y., Liu L., Weiner H.L. IL-4 is a differentiation factor for transforming growth factor-β secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis. Eur. J. Immunol. 28:1998;2780-2790.
124. Benerzra M., Vlodavsky I.L., Ishai-Michaeli R., Neufeld G., Bar-Shavit R. Thrombin-induced release of active basic fibroblast growth factor-heparan sulfate complexes from subendothelial extracellular matrix. Blood. 81:1993;3324-3331.
125. Piccirillo C., Chang Y., Prud'homme G.J. Transforming growth factor beta-1 (TGF-β1) somatic gene therapy prevents autoimmune disease in NOD mice. J. Immunol. 161:1998;3950-3956.
126. Piccirillo C., Prud'homme G.J. Prevention of experimental allergic encephalomyelitis by intramuscular gene therapy with cytokine-encoding plasmid vectors. Hum. Gen. Ther. 10:1999;1915-1922.
127. Raz E., Lotz M., Bairs S.M., Berry C.C., Eisenberg R.A., Carson D. Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene therapy ameliorates experimental colitis in rats. Eur. J. Gastroent. Hepatol. 7:1995;341-347.
128. Long O.L. Regulation of immune responses through inhibitory receptors. Ann. Rev. Immunol. 17:1999;875-904.
129. Bertone S., Schiavetti F., Bellomo R., Vitale C., Ponte M., Moretta L., Mingari M.C. Transforming growth factor-beta-induced expression of CD94/NKG2a inhibitory receptors in human T lymphocytes. Eur. J. Immunol. 29:1999;23-29.
130. Wahl S.M., Hunt D.A., Wakefield L.M., McCartney-Francis N.L., Wahl L.M., Roberts A.B., Sporn M.B. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc. Natl. Acad. Sci. 84:1987;5788-5792.
131. Fan K., Ruan Q., Sensenbrenner L., Chen B. Transforming growth factor-beta 1 bifunctionally regulates murine macrophages proliferation. Blood. 79:1992;1679-1685.
132. McCartney-Francis N.L., Mizel D., Wong H., Wahl L., Wahl S.M. TGF-β regulates production of growth factors and TGF-β by human peripheral blood monocytes. Growth Factors. 4:1990;27-35.
133. Cerwenka A., Bevec D., Madjic O., Knapp W., Holter W. TGF-β1 is a potent inducer of human effector T cells. J. Immunol. 153:1994;4367-4377.
134. Riedl E., Strobl H., Majdic O., Knapp W. TGF-β1 promotes in vitro generation of dendritic cells by protecting progenitor cells from apoptosis. J. Immunol. 153:1997;L4367-4377.
135. Rafferty D.E., Montgomery P.C. The effects of transforming growth factor-beta and interleukins 2, 5 and 6 on immunoglobulin production in cultured rat salivary gland tissues. Oral Microbiol. Immunol. 10:1995;81-86.
136. Zettel L., Clark D.A., Ernst P.B. Transforming growth factor-beta 1 enhances IgG and IgA sheep red blood cell responses. Int. Immunol. 4:1992;975-983.
137. +B cells regardless of the method of B cell activation. J. Immunol. 148:1992;3830-3836.
138. Giladi E., Raz E., Karmeli F., Okon E., Rachmilewitz D. Transforming growth factor-beta gene therapy ameliorates experimental colitis in rats. Eur. J. Gastroent. Hepatol. 7:1995;341-347.
139. Danielpour D., Kim K.Y., Dart L.L., Wanabe S., Roberts A.B., Sporn M.B. Evidence for differential regulation of TGF-1 and TGF-2 expression in vivo by sandwich enzyme-linked immunosorbant assay. Piéz K.A., Sporn M.B. Transforming growth factor, chemistry, biochemistry and therapeutics. Ann. NY Acad. Sci. 593:1990;300-302.
140. Raz E., Watanabe A., Baird S.M., Eisenberg R.A., Parr T.B., Lotz M., Kipps T.J., Carson D. Systemic immunological effects of cytokine genes injected into skeletal muscle. Proc. Natl. Acad. Sci. 90:1993;4523-4527.
141. Prud'homme G.J., Kono D.H., Theofilopoulos A.N. Quantitative polymerase chain reaction analysis reveals marked overexpression of interleukin-1β, interleukin-10, and interferon-γ mRNA in the lymph nodes of lupus-prone mice. Mol. Immunol. 32:1995;495-503.
142. Balomenos D., Rumold R., Theofilopoulos A.N. Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J. Clin. Invest. 101:1998;364-371.
143. Theofilopoulos A.N. Effector and predisposing genes in murine lupus. Lupus. 7:1998;575-584.
144. Schindler H., Diefenbach A., Rollinghoff M., Bogdan C. IFN-gamma inhibits the production of latent transforming growth factor-beta 1 by mouse inflammatory macrophages. Eur. J. Immunol. 28:1998;1181-1188.
145. Chernajovsky Y., Adams G., Triantaphyllopoulos K., Ledda M.F., Podhajcer O.L. Pathogenic lymphoid cells engineered to express TGF β1 ameliorate disease in a collagen-induced arthritis model. Gene Therapy. 4:1997;553-559.
146. Kuruvilla A.P., Shah R., Hochwald G.M., Liggitt H.D., Palladino M.A., Thorbecke G.J. Protective effect of transforming growth factor β1 on experimental autoimmune disease in mice. Proc. Natl. Acad. Sci. 88:1991;2918-2921.
147. Brandes M.E., Allen J.B., Ogawa Y., Wahl S.M. Transforming growth factor beta 1 suppresses acute and chronic arthritis in experimental animals. J. Clin. Invest. 87:1991;1108-1113.
148. Song X-Y., Mili G., Jin W.W., Klinman D.M., Wahl S.M. Plasmid DNA encoding transforming growth factor-β1 suppresses chronic disease in a streptococcal cell wall-induced arthritis model. J. Clin. Invest. 101:1998;2615-2621.
149. Allen J.B., Manthey C.L., Hand A.R., Ohura K., Ellingsworth L., Wahl S.M. Rapid onset synovial inflammation and hyperplasia induced by transforming growth factor beta. J. Exp. Med. 171:1990;231-247.
150. Wyss-Coray T., Feng L., Masliah E., Ruppe M.D., Lee H.S., Toggas S.M., Rockenstein E.M., Mucke L. Increased central nervous system production of extracellular matrix components and development of hydrocephalus in transgenic mice overexpressing transforming growth factor-β1. Am. J. Pathol. 147:1995;53-67.
151. Lennart D.J., Flanders K.C., Rangers G.E., Sriram S. Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-β1. J. Immunol. 147:1991;1792-1796.
152. +T-cell subsets in autoimmunity. Curr. Opin. Immunol. 9:1997;872-883.
153. King C., Sarvetnick N. Organ-specific autoimmunity. Curr. Opin. Immunol. 9:1997;863-871.
154. +T cells. Ann. Rev. Immunol. 12:1994;635-673.
155. Paul W.E., Seder R.A. Lymphocyte responses and cytokines. Cell. 76:1994;241-251.
156. Trembleau, S. Germann, T. Gately, M.K. Adorini, L. 1995, The role of IL-12 in the induction of organ-specific autoimmune diseases, 16, 383, 386.
157. +T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol. Today. 1:1995;34-38.
158. +T cells in autoimmune diabetes through the use of TCR transgenic mice. Immunol. Rev. 169:1999;55-65.
159. Rabinovitch A. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes/Metabolism Rev. 14:1998;129-151.
160. Delovitch T.L., Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity. 7:1997;728-738.
161. Katz J.D., Benoist C., Mathis D. T helper subsets in insulin-dependent diabetes. Science. 268:1995;1185-1188.
162. Prud'homme G.J., Chang Y. Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/IgG1 fusion protein. Gene Therapy. 6:1999;771-777.
163. Wang D., Andre I., Gonzalez A., Katz J.D., Aguet M., Benoist C., Mathis D. Interferon-gamma impacts at multiple points during the progression of autoimmune diabetes. Proc. Natl. Acad. Sci. U S A. 94:1997;13844-13849.
164. Trembleau S., Penna G., Gregori S., Gately M.K., Adorini L. Deviation of pancreas infiltrating cells to Th2 by interleukin 12 antagonists administration inhibits autoimmune diabetes. Eur. J. Immunol. 27:1997;2330-2339.
165. Grewall I.S., Flavell R.A. New insights into insulin dependent diabetes mellitus from studies with transgenic mouse models. Lab. Invest. 76:1997;3-10.
166. Chang Y., Prud'homme G.J. Intramuscular administration of expression plasmids encoding interferon-gamma-receptor/IgG1 or IL-4/IgG1 chimeric proteins protects from autoimmunity. J. Gene Med. 1999.
167. Pakala S.V., Kurrer M.O., Katz J.D. T helper 2 (Th2) cells induce acute
168. King C., Davies J., Mueller R., Lee M.S., Krahl T., Yeung B., O'Connor E., Sarvetnick N. TGF-beta 1 alters APC preference, polarizing islet antigen responses toward a Th2 phenotype. Immunity. 8:1998;601-613.
169. Moritani M., Yoshimoto K., Wong S.F., Tanaka C., Yamaoka T., Sano T., Komagata Y., Miyazaki J., Kikutani H., Itakura M. Abrogation of autoimmune diabetes in nonobese diabetic mice and protection against effector lymphocytes by transgenic paracrine TGF-beta 1. J. Clin. Invest. 1998;499-506.
170. +suppressor T cell completely prevents spontaneous autoimmune diabetes and recurrent diabetes in syngeneic islet-transplanted NOD mice. J. Autoimmun. 9:1996;331-339.
171. Sanvito F., Nichols A., Herrera P.L., Huarte J., Wohlwend A., Vassalli J.D., Orci L. TGF-beta 1 overexpression in murine pancreas induces chronic pancreatitis and, together with TNF-alpha, triggers insulin-dependent diabetes. Biochem. Biophys. Res. Comm. 26:1995;1279-1286.
172. Zekzer D., Wang S.F., Wen L., Altieri M., Gurlo T., Von Grafenstein H., Sherwin R.S. Inhibition of diabetes by an insulin-reactive CD4 T-cell clone in the nonobese diabetic mice. Diabetes. 46:1997;1124-1132.
173. Olsson T. Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T cell autoimmunity in experimental allergic encephalomyelitis and multiple sclerosis. Immunol. Rev. 144:1995;245-268.
174. Owens T., Renno T., Taupin V., Krakowski M. Inflammatory cytokines in the brain: does the CNS shape immune responses. Immunol. Today. 15:1994;566-571.
175. Powell M.B., Mitchell D., Lederman J., Buckmeier J., Zamvil S.S., Graham M., Ruddle N.H., Steinman L. Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int. Immunol. 2:1990;539-544.
176. Swanborg R.H. Animal models of human disease experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease. Clin. Immunol. Immunopathol. 77:1995;4-13.
177. Racke M.K., Bonomo A., Scott D.E., Cannella B., Levine A., Raine C.S., Shevach E.M., Rocken M. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med. 180:1994;1961-1966.
178. Inobe J.I., Chen Y., Weiner H.L. In vivo administration of IL-4 induces TGF-β-producing cells and protects animals from experimental autoimmune encephalomyelitis. Ann. NY Acad. Sci. 778:1996;390-392.
179. Druet P., Sheela R., Pelletier L. Th1 and Th2 cells in autoimmunity. Chem. Immunol. 63:1996;158-170.
180. Racke M.K., Cannella B., Albert P., Sporn M., Raine C.S., McFarlin D.E. Evidence of endogenous regulatory function of transforming growth factor-β1 in experimental allergic encephalomyelitis. Int. Immunol. 4:1992;615-620.
181. Falcone M., Rajan A.J., Bloom B.R., Brosnan C.F. A critical role for IL-4 in regulating disease severity in experimental allergic encephalomyelitis as demonstrated in IL-4-deficient C57BL/6 mice and BALB/c mice. J. Immunol. 1998;4822-4830.
182. Miller A., Lider O., Roberts A.B., Sporn M.B., Weiner H.L. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor β after antigen-specific triggering. Proc. Natl. Acad. Sci. U S A. 89:1992;421-425.
183. Khoury S.J., Hancock W.W., Weiner H.L. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor β, interleukin 4, and prostaglandin E expression in the brain. J. Exp. Med. 176:1992;1355-1364.
184. Hancock W.W., Polanski M., Zhang J., Blogg N., Weiner H.L. Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E. Am. J. Pathol. 147:1995;1193-1199.
185. Renno T., Krakowski M.K., Piccirillo C., Lin J., Owens T. TNFα expression by resident microglia and infiltrating leukocytes in the central nervous system of mice with experimental allergic encephalomyelitis. J. Immunol. 154:1995;944-953.
186. +T cells. J. Exp. Med. 183:1996;2669-2674.
187. 1. J. Immunol. 146:1991;3012-3017.
188. Ludovic-Croxford J., Triantaphyllapoulos K., Podhajcer L.L., Feldmann M., Baker D., Chernajovsky Y. Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system. J. Immunol. 160:1998;5181-5187.
189. Hartikka J., Sawdey M., Cornefert-Jensen F., Margalith M., Barnhart K., Nosasco M., Vahlsing H.L., Meek J., Marquet M., Hobart P., Norman J., Manthorpe M. An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum. Gene. Ther. 7:1996;1205-1217.
190. Shi F.D., Bai X.F., Xiao B.G., van der Meide P.H., Link H. Nasal administration of multiple antigens suppresses experimental autoimmune myasthenia gravis, encephalomyelitis and neuritis. J. Neurol. Sci. 155:1998;1-12.
191. Schluesener H.J., Lider O. Transforming growth factors beta 1 and beta 2: cytokines with identical immunosuppressive effects and a potential role in the regulation of autoimmune T cell function. J. Neuroimmunol. 24:1989;249-258.
192. Chen L.Z., Hochwald G.M., Huang C., Dakin G., Tao H., Cheng C., Simmons W.J., Dranoff G., Thorbeck G.J. Gene therapy in allergic encephalomyelitis using myelin basic protein-specific T cells engineered to express latent transforming growth factor-beta 1. Proc. Natl. Acad. Sci. 95:1998;12516-12521.
193. Diab A., Michael L., Wahren B., Deng G.M., Bjork J., Hedlunk G., Zhu J. Linomide suppresses acute experimental autoimmune encephalomyelitis in Lewis rats by counteracting the imbalance of pro-inflammatory versus anti-inflammatory cytokines. J. Neuroimmunol. 85:1998;146-154.
194. Kjellen P., Issazadeh S., Olsson T., Holmdahl R. Genetic influence on disease course and cytokine response in relapsing experimental allergic encephalomyelitis. Int. Immunol. 10:1998;333-340.
195. Chen Y., Hancock W.W., Marks R., Gonnella P., Weiner H.L. Mechanisms of recovery from experimental autoimmune encephalomyelitis: T cell deletion and immune deviation in myelin basic protein T cell receptor transgenic mice. J. Neuroimmunol. 82:1998;149-154.
196. Croxford J.L., Triantaphyllopoulos K., Podhajcer O.L., Feldman M., Baker D., Chernajovsky Y. Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system. J. Immunol. 160:1998;5181-5187.
197. Santambrogio L., Lees M.B., Sobel R.A. Altered peptide ligand modulation of experimental allergic encephalomyelitis: immune responses within the CNS. J. Neuroimmunol. 81:1998;1-13.
198. Iwashashi T., Koh C.S., Inoue A., Yanagisawa N. Tumor necrosis factor-alpha and transforming growth factor-beta production by isolated mononuclear cells from the spinal cords of Lewis rats with experimental autoimmune encephalomyelitis. Tohoku J. Exp. Med. 183:1997;123-133.
199. Bai X.F., Shi F.D., Xiao B.G., Li H.L., van der Meide P.H., Link H. Nasal administration of myelin basic protein prevents relapsing experimental autoimmune encephalomyelitis in DA rats by activating regulatory cells expressing IL-4 and TGF-beta mRNA. J. Neuroimmunol. 80:1997;65-75.
200. Mujtaba M.G., Soos J.M., Johnson H.M. CD4 T suppressor cells mediate interferon tau protection against experimental allergic encephalomyelitis. J. Neuroimmunol. 75:1997;35-42.
201. Brenner T., Brocke S., Szafer F., Sobel R.A., Parkinson J.F., Perez D.H., Steinman L. Inhibition of nitric oxide synthase for treatment of experimental autoimmune encephalomyelitis. J. Immunol. 158:1997;2940-2946.
202. Crisi G.M., Santambrogio L., Hochwald G.M., Smith S.R., Carlino J.A., Thorbecke G.J. Staphylococcal enterotoxin B and tumor-necrosis factor-alpha-induced relapses of experimental allergic encephalomyelitis: protection by transforming growth factor-beta and interleukin-10. Eur. J. Immunol. 25:1995;3035-3040.
203. Issazadeh S., Mustafa M., Ljungdahl A., Hojeberg B., Dagerlind A., Elde R. Interferon gamma, interleukin-4 and transforming growth factor beta in experimental autoimmune encephalomyelitis in Lewis rats: dynamics of cellular mRNA expression in the central nervous system and lymphoid cells. J. Neurosci. Res. 40:1995;579-590.
204. Santos L.M., Al-Sabbagh A., Londono A., Weiner H.L. Oral tolerance to myelin basic protein induces regulatory TGF-beta-secreting T cells in Peyer's patches of SJL mice. Cellular Immunol. 157:1994;439-447.
205. Stevens D.B., Gould K.E., Swanborg R.H. Transforming growth factor-beta 1 inhibits tumor necrosis factor-alpha/lymphotoxin production and adoptive transfer of disease by effector cells of autoimmune encephalomyelitis. J. Neuroimmunol. 51:1994;77-83.
206. Mustafa M., Vingsboundgahl C., Hojeberg B., Holmdahl R. The major histocompatibility complex influences myelin basic protein 63-88-induced T cell cytokine profile and experimental autoimmune encephalomyelitis. Eur. J. Immunol. 23:1993;3089-3095.
207. Johns L.D., Sriram S. Experimental allergic encephalomyelitis: neutralizing antibody to TGF beta 1 enhances the clinical severity of the disease. J. Neuroimmunol. 47:1993;1-7.
208. Okuda Y., Sakoda S., Yanagihara T. The pattern of cytokine gene expression in lymphoid organs and peripheral blood mononuclear cells of mice with experimental allergic encephalomyelitis. J. Neuroimmunol. 87:1998;147-155.
209. Koh D.R. Oral tolerance: mechanisms and therapy of autoimmune diseases. Ann. Acad. Sci. Singapore. 27:1998;47-53.
210. Boirivant M., Fuss I.J., Chu A., Strober W. Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J. Exp. Med. 188:1998;1929-1939.
211. Ludviksson B.R., Ehrhardt R.O., Strober W. TGF-beta production regulates the development of the 2,4,6-trinitrophenol-conjugated keyhole limpet hemocyanin-induced colonic inflammation in IL-2 deficient mice. J. Immunol. 159:1997;3622-3628.
212. Rogler G., Andus T. Cytokines and inflammatory bowel disease. World J. Surg. 22:1998;383-389.
213. Neurath M.F., Fuss I., Kelsall B.L., Presky D.H., Waegell W., Strober W. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J. Exp. Med. 183:1996;2605-2616.
214. Shevach E.M. Organ-specific diseases. Paul W.E. Fundamental immunology. 4th edn. 1999;1089-1125 Lippincott-Raven, Philadelphia.
215. Polanski M., Melican N.S., Zhang J., Weiner H.L. Oral administration of the immunodominant B-chain of insulin reduces diabetes in a co-transfer model of diabetes in the NOD mouse and is associated with a switch from Th1 to Th2 cytokines. J. Autoimmun. 10:1997;339-346.
216. Koevary S.B. Prevention of diabetes in BB/Wor rats by injection of peritoneal exudate cells cultured in the presence of transforming growth factor beta (TGF-beta) and islet cells. Diabetes Res. 27:1994;1-14.
217. Maron R., Palanivel V., Weiner H.L., Harn D.A. Oral administration of schistosome egg antigens and insulin B-chain generates and enhances Th2-type responses in NOD mice. Clin. Immunol. Immunopathol. 87:1998;85-92.
218. Han H.S., Jun H.S., Utsugi T., Yoon J.W. Molecular role of TGF-β, secreted by a new type of CD4+suppressor T cell, NY4.2, in the prevention of autoimmune IDDM in NOD mice. J. Autoimmun. 10:1997;299-307.
219. +T cell clone, IS.2.15, has in vitro immunosuppressive properties. Eur. J. Immunol. 22:1992;2017-2023.
220. Xiao B.G., Zhang G.X., Shi F.D., Ma C.G., Link H. Decrease of LFA-1 is associated with upregulation of TGF-beta in CD4(+) T cell clones derived from rats nasally tolerized against experimental autoimmune myasthenia gravis. Clin. Immunol. Immunopathol. 89:1998;196-204.
221. Ma C.G., Zhang G.X., Xiao B.G., Wang Z.Y., Link J., Olssor T., Link H. Mucosal tolerance to experimental autoimmune myasthenia gravis is associated with down-regulation of AChR-specific IFN-gamma-expressing Th1-like cells and up-regulation of TGF-beta mRNA in mononuclear cells. Ann. NY Acad. Sci. 778:1996;273-287.
222. Peng B., Li Q., Roberge F.G., Chan C.C. Effect of transforming growth factor beta-1 in endotoxin- induced uveitis. Invest. Opthal. Vis. Sci. 38:1997;257-260.
223. Song X.Y., Gu M., Jin W.W., Klinman D.M., Wahl S.M. Plasmid DNA encoding transforming growth factor-beta 1 suppresses chronic disease in a streptococcal cell wall-induced arthritis model. J. Clin. Invest. 101:1998;2615-2621.
224. Chen W., Jin W., Cook M., Weiner H.L., Wahl S.M. Oral Delivery of group A streptococcal cell walls augments circulating TGF-beta and suppresses streptococcal cell wall arthritis. J. Immunol. 161:1998;6297-6304.
225. Guimaraes V.C., Quintans J., Filfalen M.E., Straus F.H., Fields P.E., Medeiros-Neto G., DeGroot L.J. Immunosuppression of thyroiditis. Endocrinol. 137:1996;2199-2207.
226. Anscher M.S., Kong F.M., Jirtle R.L. The relevance of transforming growth factor-beta 1 in pulmonary disease after injury from radiation therapy. Lung Cancer. 19:1998;109-120.
227. Zhang K., Phan S.H. Cytokines and pulmonary fibrosis. Biol. Sig. 5:1996;232-239.
228. Matrat M., Lardot C., Huaux F., Broeckaert F., Lison D. Role of urokinase in the activation of macrophage-associated TGF-beta in silica-induced lung fibrosis. J. Toxicol. Environ. Health. 55:1998;359-371.
229. Talbot D., Dark J.H., Kirby J.A. Differential effects of cyclosporin A and tacrolimus on the production of TGF-beta: implications for the development of obliterative bronchiolitis after lung transplantation. Transplant International. 11:1998;S325-S327.
230. Haustein U.F., Anderegg U. Pathophysiology of scleroderma: an update. J. Eur. Acad. Dermatol. Venereal. 11:1998;1-8.
231. Kitamura M., Suto T.S. TGF-beta and glomerulonephritis: anti-inflammatory versus prosclerotic actions. Nephrol. Dial. Transplan. 12:1997;669-679.
232. Liem L.M., Fibbe W.E., van Houwelingen H.C., Goulmy E. Serum transforming growth factor-beta 1 levels in bone marrow transplant recipients correlate with blood cell counts and chronic graft-versus-host disease. Transplantation. 67:1999;59-65.
233. Barral A., Barral-Netto M., Yong E.C., Brownell C.E., Twardzik D.R., Reed S.G. Transforming growth factor β as a virulence mechanism for Leishmania braziliensis. Proc. Natl. Acad. Sci. U S A. 90:1993;3442-3446.
234. Valdez H., Lederman M.M. Cytokines and cytokine therapies in HIV infection. AIDS Clinical Review. 1:1997-98;187-228.
235. +immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188:1998;287-296.